Roche Announces FDA Approval of Actemra (Tocilizumab) for Hospitalized Adults with COVID-19

Roche Pharma's official WeChat message: On December 21, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Actemra® (tocilizumab) intravenous injection (IV) for the treatment of adult hospitalized patients with COVID-19. According to reports, Actemra is the first monoclonal antibody approved by the FDA for treating COVID-19 and is recommended for a single 60-minute intravenous infusion. In China, Actemra has also been included in the "Diagnosis and Treatment Protocol for COVID-19 (Trial Version 9)."